Abstract
The extent of left ventricular myocardial hypertrophy is generally considered to be a predictor of cardiac morbidity and mortality (Devereux et al. 1984; Levy et al. 1988, 1990). The evolution of left ventricular hypertrophy has been causally related to coronary artery disease (CAD), arterial hypertension, and increased cardiac output (Devereux 1990; Messerli and Schmieder 1990; Koren et al. 1991). This is apparently also the case with patients with end-stage renal disease undergoing chronic intermittent hemodialysis treatment (Bullock et al. 1984; Kramer et al. 1986a,b; Harnett et al. 1988; Silberberg et al. 1989).Whether secondary hyperparathyroidism significantly contributes to myocardial fibrosis in patients on hemo- or peritoneal dialysis does, however, appear doubtful at the present time (London et al. 1987a,b; Mall et al. 1990; Hüting et al. 1991a,b).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bullock RE, Amer HA, Simpson I,Ward MK, Hall RJC (1984) Cardiac abnormalities and exercise tolerance in patients receiving renal replacement therapy, Br Med J 289: 1479–1484
Devereux RB (1990) Does increased blood pressure cause left ventricular hypertrophy or vice versa Ann Intern Med 112: 157–158
Devereux RB, Drayer JIM, Chien S, Pickering TG, Letcher RL, DeYoung JL, Sealey JE, Laragh JH (1984) Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 54: 592–595
Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD (1988) Left ventricular hypertrophy in end-stage renal disease. Nephron 48: 107–115
Hüting J, Kramer W,Wizemann V, Schütterle G (1991a) Effects of secondary hyperparathyroidism on left ventricular hypertrophy and function in patients on different renalreplacement therapies. In: Timio M, Wizemann V (eds) Cardionephrology. Wichtig, Milan, pp 119–122
Hüting J, Kramer W, Kühn K, Schütterle G, Wizemann V (1991b) Risk factors for diastolic left ventricular dysfunction in patients on continuous ambulatory peritoneal dialysis (CAPD) In: Timio M, Wizemann V (eds) Cardionephrology. Wichtig, Milan, pp 321–324
Klaus D, Schwarze D, Lederle RM, Saul F (1991) Behandlung mit rekombinantem humanem Erythropoietin. Nieren Hochdruckkrankheiten 20: 28–35
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114: 345–352
Kramer W,Wizemann V,Thormann J, Kindler M, Mueller K, Schlepper M (1986a) Cardiac dysfunction in patients on maintenance hemodialysis. I. The importance of associated heart disease in determining alteration of cardiac performance. Contrib Nephrol 52: 97–109
Kramer W,Wizemann V, Lämmlein G,Thormann J, Kindler M, Schlepper M, Schütterle G (1986b) Cardiac dysfunction in patients on maintenance hemodialysis. II. Systolic and diastolic properties of the left ventricle assessed by invasive methods. Contrib Nephr 52: 110–124
Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med 108: 7–13
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med 322: 1561–1566
London GM, DeVernejoul MC, Fabiani F, Marchais SJ, Guerin AP, Metivier F, London AM
Llach F (1987a) Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 32: 900–907
London GM, Fabiani F, Marchais SJ, DeVernejoul MC, Guerin AP, Safar ME, Metivier F, Llach F (1987b) Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 31: 973–980
Low I, Grützmacher P, Bergmann M, Schoeppe W (1989) Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 31: 26–30
Messerli FH, Schmieder RF (1990) Arterielle Hypertonie, linksventrikuläre Hypertrophie und plötzlicher Herztod. Dtsch Med Wochenschr 115: 1682–1687
Mall G, Huther W, Schneider J, Lundin P, Ritz E (1990) Diffuse intermyocardocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5: 39–44
Sahn DJ, DeMaria A, Kisslo J,Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072–1083
Silberberg JS, Barre PE, Prichard SS, Sniderman AD (1989a) Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286–290
Silberberg JS, Rahal DP, Patton DR, Sniderman AD (1989b) Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 64: 222–224
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schütterle, G., Kramer, W., Schäfer, R., Kaufmann, J., Wizemann, V. (1992). Cardiological Findings in Patients with End-Stage Renal Failure Under Treatment with Erythropoietin. In: Pagel, H., Weiss, C., Jelkmann, W. (eds) Pathophysiology and Pharmacology of Erythropoietin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77074-6_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-77074-6_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77076-0
Online ISBN: 978-3-642-77074-6
eBook Packages: Springer Book Archive